Skip to main content
    F

    Fortress Biotech Inc (FBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.82
    +0.11 (+6.43%)

    Market Cap: $62.70M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Fortress Biotech Inc (FBIO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Fortress Biotech (FBIO) has a market cap of $62.70M. It holds $126.61M more cash than debt, 201.93% of its market cap. It kept 177.32% of revenue as net income over the last 12 months.

    Total Valuation

    Market Cap$62.70M
    Latest price (Nov 17, 2026)$1.82

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 13, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 6.15% in the quarter ended Sep 30, 2026 and grew 30.89% a year over 2 years.

    Shares Outstanding33.75M
    Shares Change (YoY)+23.87%
    Shares Change (QoQ)+6.15%
    Share Count Growth (2Y CAGR)+30.89%

    Valuation Ratios

    Sales and book value multiples are 0.9x and 0.4x.

    P/E Ratio0.8x
    Forward P/E0.7x
    P/S Ratio0.9x
    Forward P/S0.8x
    P/B Ratio0.4x
    P/TBV Ratio0.5x
    P/OCF Ratio0.5x

    Valuation history and multiples

    Price Statistics

    The stock is down 30.53% over 52 weeks and trades 13.33% below its 50-day average.

    Beta (1Y)1.39
    52-Week Change-30.53%
    1-Month Change-2.67%
    3-Month Change-36.14%
    6-Month Change-28.06%
    5-Year Change-96.07%
    10-Year Change-94.62%
    Total Return (1Y)-30.53%
    Total Return (3Y CAGR)-4.51%
    Total Return (5Y CAGR)-47.69%
    Return vs SPY (1Y)-43.39%
    Max Drawdown (1Y)-60.96%
    Max Drawdown (3Y)-64.27%
    Sharpe Ratio (1Y)-0.59
    Correlation with SPY (1Y)0.30
    50-Day Average$2.10
    200-Day Average$2.70
    52-Week Range$1.71 to $4.53
    RSI (14 Days)42.1
    Average Volume (20 Days)224.55K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.93x current liabilities, and total debt is 0.16x shareholder equity.

    Current Ratio2.93x
    Quick Ratio2.82x
    Debt / Equity0.16x
    Debt / EBITDA0.18x
    Interest Coverage14.28x

    Returns and Efficiency

    Return on invested capital is 57.03% and return on equity is 77.57% over the last 12 months.

    Return on Equity (ROE)77.57%
    Return on Assets (ROA)44.29%
    Return on Invested Capital (ROIC)57.03%
    Return on Capital Employed (ROCE)64.27%
    ROA (5Y Average)-61.56%
    Asset Turnover0.30x
    Inventory Turnover2.97x
    Receivables Turnover1.66x
    Cash Conversion Cycle-474 days

    Taxes

    Income tax took 5.18% of pretax income over the last 12 months.

    Income Tax (TTM)$5.40M
    Effective Tax Rate5.18%

    Scores

    FBIO has an Altman Z-Score of -0.37, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score-0.37
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $69.99M over the last 12 months is up 12.27% from the 12 months before.

    Revenue$69.99M
    Revenue Growth (YoY)+12.27%
    Gross Profit$46.31M
    Operating Income-$29.56M
    Pretax Income$104.17M
    Net Income$124.11M
    EBITDA$140.57M
    EBIT$133.98M
    Reported EPS (TTM)$2.30

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 57.10% of the $280.21M in total assets.

    Cash and Equivalents$152.19M
    Total Debt$25.58M
    Net Cash$126.61M
    Net Cash Per Share$3.75
    Working Capital$138.60M
    Shareholder Equity$160.00M
    Book Value Per Share$4.74
    Tangible Book Value$135.46M
    Tangible Book Per Share$4.01
    Total Assets$280.21M
    Total Liabilities$103.19M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow$125.83M
    FCF Per Share$3.77
    Depreciation and Amortization$6.60M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -42.23%.

    Gross Margin66.16%
    Operating Margin-42.23%
    Pretax Margin148.83%
    Net Margin177.32%
    EBITDA Margin200.84%
    EBIT Margin191.41%
    Gross Margin (5Y Average)63.27%

    Growth

    Revenue fell 5.83% a year over 3 years.

    Revenue Growth (3Y CAGR)-5.83%
    Revenue Growth (5Y CAGR)+6.77%

    Revenue and profit by year

    Dividends and Yields

    FBIO does not pay a dividend.

    Earnings Yield125.00%
    Buyback Yield91.11%

    Stock Splits

    The last split was a 1-for-15 reverse split on Oct 10, 2023.

    Last Split DateOct 10, 2023
    Split TypeReverse split
    Split Ratio1:15

    Peer Position

    Against 7 similar companies, FBIO has the lowest P/S.

    P/S Ratio0.9x vs 12.3x median
    ROIC57.03% vs -177.56% median
    Revenue Growth (Trailing 4 Quarters, YoY)+12.27% vs -37.25% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 33.80% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+33.80%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About FBIO

    What is FBIO's market cap?

    Fortress Biotech has a market cap of $62.70M.

    What is FBIO's P/E ratio?

    Fortress Biotech has a trailing P/E ratio of 0.8x and a forward P/E of 0.7x.

    How many shares of FBIO are outstanding?

    Fortress Biotech has 33.75M shares outstanding. The count is up 23.87% from a year earlier.

    Does FBIO pay a dividend?

    No. Fortress Biotech does not pay a dividend.

    How much debt does FBIO have?

    Fortress Biotech has $25.58M of total debt and $152.19M of cash and equivalents, a net cash position of $126.61M.